Insider selling is routine in both dollar amount and seniority level. No bearish signal. Monitor the next earnings release for any guidance changes, but this cluster alone does not warrant action.
EXEL drugs
EXEL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 29 $50.32entry
- T+1 · 6mo ago −0.08%α −0.35% · $50.28
- T+5 · 6mo ago +2.55%α +2.84% · $51.60
- T+20 · 5mo ago +8.85%α +12.48% · $54.77
- T+60 · 3mo ago +8.17%α +7.24% · $54.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two EVPs at Exelixis sold a combined $3.79M in open-market sales over a week, with no insider buying. The sales are modest relative to the $12.9B market cap (~0.03%), and the cluster is driven by two senior commercial and R&D executives, not the CEO/CFO. Per the asymmetry rule, cluster sales are not amplified beyond the proportionality band, and the dollar amount is trivial for a company of this size.
Key Financial Metrics
Key Facts
- EVP Commercial Patrick J. Haley sold 32,100 shares at $49.81 for $1.60M on 2026-05-20.
- EVP R&D Dana Aftab sold 43,451 shares at $50.35 for $2.19M on 2026-05-26.
- Total insider sales: $3.79M, representing ~0.03% of Exelixis's $12.9B market cap.
- No insider purchases occurred in the cluster window.
- A director (David Edward Johnson) received a non-cash grant of 19,133 shares on 2026-05-27 with $0 economic value.
- Prior 30-day insider activity included 4 sells totaling $5.9M, consistent with routine selling patterns.
Financial Impact
Total open-market sales of $3.79M, or ~0.03% of market cap, immaterial relative to company size.
Risk Factors
- No material risk identified from this insider activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-EXEL-1780086707364 |
Track record
16 reports on EXEL
0 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +21.97% at T+60 after the Feb 28, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $70.58 to $70.70 Now $67.10 −4.93% ▲ +0.17% −1.15% vs SPY
- Nov 9, 20267d ago SC 13D/A Bearish 5/10 Entry $70.58 to $70.70 Now $67.10 +4.93% ▼ −0.17% +1.15% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $69.39 to $70.13 Now $67.10 −3.30% ▲ +1.07% +1.55% vs SPY
- Oct 20, 202627d ago Institutional Cluster Neutral 2/10 Entry $64.58 to $65.31 Now $67.10 +3.90% ▲ +1.13% +2.31% vs SPY
- Oct 12, 20265w ago Institutional Cluster Neutral 3/10 Entry $59.82 to $59.51 Now $67.10 +12.17% ▼ −0.52% −0.51% vs SPY
- Sep 11, 20269w ago 8-K Bearish 6/10 Entry $56.12 to $56.21 Now $67.10 −19.57% ▼ −0.16% −0.61% vs SPY
- Jun 3, 202623w ago Insider Cluster Neutral 2/10 Entry $52.39 to $52.69 Now $67.10 +28.08% ▲ +0.57% +3.17% vs SPY
- May 29, 202624w ago 8-K Neutral 3/10 Entry $50.20 to $48.49 Now $67.10 +33.67% ▼ −3.41% −3.55% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Viewing Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers